NEW DELHI: While the recently concluded India–European Union Free Trade Agreement (FTA) drew attention for its implications for automobiles, textiles and spirits, its most transformative impact may lie in healthcare manufacturing, pharmaceuticals and medical technology — sectors central to India's economy and global health security.
At the heart of the agreement is the opening up of the European Union's $572.3 billion pharmaceuticals and medical devices market to Indian manufacturers, a shift the Department of Pharmaceuticals, the Ministry of Chemicals and Fertilizers described as a strategic opportunity to scale production, generate skilled employment, strengthen MSME participation and deepen India's integration into global supply chains. The govt positioned the deal as reinforcing India's role as a "reliable partner" and the "pharmacy of the world," signalling that healthcare, rather than traditional tariff-sensitive sectors, may be where the FTA delivers its most enduring gains.
Two new international research analyses, published over past 24-hours, support this assessment. A strategic study released by global consulting firm Frost & Sullivan characterises the agreement as a "supply-chain reset" rather than a conventional tariff-cutting exercise. Titled "The India–EU FTA: Beyond Tariff Arithmetic – A Supply Chain Reset that Brings Globalisation and Trade Diversification," the report argues that the deal repositions India and Europe within a more resilient and diversified global trade architecture at a time when geopolitical fragmentation is reshaping supply networks.
For healthcare, the implications are substantial. Pharmaceuticals, medical devices, diagnostic equipment and health-technology components depend on complex cross-border production systems. Lower trade costs, smoother logistics and regulatory cooperation could integrate India more deeply into high-value European supply chains, strengthening its position as a global hub for generic medicines, active pharmaceutical ingredients (APIs) and cost-effective medical devices.
A policy brief by the Kiel Institute for the World Economy in Germany frames the FTA as a strategic response to the over-concentration of global trade routes, particularly dependence on the US–China corridor. The brief highlights India's status as the world's largest producer of generic medicines by volume, with pharmaceutical exports worth $23.4 billion in 2024.
"With chemical tariffs of up to 22% eliminated on most products and reduced regulatory barriers, Indian pharmaceutical and chemical exports to Europe will receive a significant boost," the Kiel Institute noted. It added that streamlined procedures and mutual recognition mechanisms would build on the credibility Indian manufacturers earned during the COVID-19 pandemic, when they supplied vaccines and treatments globally.
Beyond export growth, health economists point to longer-term systemic benefits. More resilient healthcare supply chains directly affect access to essential medicines, vaccines and medical equipment — vulnerabilities that became evident during pandemic-era disruptions. Experts say the FTA could gradually improve reliability and predictability in sourcing critical healthcare inputs over the next decade.
The Ministry of Commerce and Industry also highlighted gains for India's medical devices sector. "With tariffs of up to 6.7% eliminated across 99.1% of trade lines, Indian exports of medical instruments, lenses, diagnostic devices and testing equipment are expected to become more competitive in Europe," it said.
Industry stakeholders, however, stress that regulatory alignment will determine whether the opportunity translates into sustainable growth.
Rajiv Nath, Forum Coordinator of the Association of Indian Medical Devices Industry (AiMeD), said the agreement must ensure fair competition. "With regulatory alignment and safeguards against predatory imports, the FTA can unlock high-value collaboration and support India's ambition to become a top-five global MedTech hub under mutual recognition agreements based on common ISO standards," Nath said.
"India's pharma exports to the EU are already growing strongly, reaching USD 3.55 billion between April and December FY26—a 10.6% increase year on year. By reducing non-tariff barriers and improving transparency, customs processes, and regulatory alignment, the agreement lowers risks for exporters and ensures more dependable medicine supplies for Europe. This stability supports long-term planning, investment, and a stronger partnership between India and the EU in healthcare," said Namit Joshi, Chairman, Pharmexcil.
From a life sciences and chemicals perspective, the deal could reshape sourcing economics. Mayank Singhal, Vice Chairperson and Managing Director of PI Industries, stresses that the elimination of duties would support deeper integration into global pharmaceutical value chains. "For active pharmaceuticals ingredients (API) and contract development and manufacturing org (CDMO) players, this changes the economics. It also opens opportunities for closer partnerships with European innovators and more integrated, high-value solutions," he said.
The benefits may also flow directly to Indian patients. Dr Dharminder Nagar, Managing Director of Paras Health and Co-Chair, FICCI Healthcare Committee, noted that Indian hospitals depend heavily on advanced medical and diagnostic equipment imported from Europe.
"Tariff elimination will reduce input costs, enable wider adoption of advanced technologies, improve outcomes, and ultimately translate into more affordable, higher-quality care," he said.
From an oncology perspective, the opportunity is significant but nuanced. Arpan Talwar of Art of Healing Cancer said the FTA could ease access for Indian generics and biosimilars in Europe, but warned that stricter intellectual property and regulatory requirements could raise costs for smaller players. "If balanced well, with safeguards for affordability and access, the agreement can support sustainable cancer care on both sides," he said.
Start a Conversation
Post comment